(Q38096468)

English

Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries

scientific article published on 08 April 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 August 2017

Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries (English)

1 reference

Europe PubMed Central

28 August 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

B Godman

1

1 reference

Europe PubMed Central

28 August 2017

B Wettermark

2

1 reference

Europe PubMed Central

28 August 2017

J Miranda

3

1 reference

Europe PubMed Central

28 August 2017

M Bennie

4

1 reference

Europe PubMed Central

28 August 2017

A Martin

5

1 reference

Europe PubMed Central

28 August 2017

R E Malmström

6

1 reference

Europe PubMed Central

28 August 2017

publication date

8 April 2013

1 reference

Europe PubMed Central

28 August 2017

International Journal of Clinical Practice

1 reference

Europe PubMed Central

28 August 2017

67

1 reference

Europe PubMed Central

28 August 2017

9

1 reference

Europe PubMed Central

28 August 2017

853-862

1 reference

Europe PubMed Central

28 August 2017

Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Utilisation of angiotensin receptor blockers in Sweden: combining survey and register data to study adherence to prescribing guidelines

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Focus on the ONTARGET results.

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Potential savings without compromising the quality of care

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Different versions of the anatomical therapeutic chemical classification system and the defined daily dose--are drug utilisation data comparable?

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Coping with changes in the Defined Daily Dose in a longitudinal drug consumption database

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Interpreting the results of observational research: chance is not such a fine thing

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Using clinical evidence

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

A cluster randomized controlled trial aimed at implementation of local quality improvement collaboratives to improve prescribing and test ordering performance of general practitioners: study protocol

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

What Happened at Hawthorne?: New evidence suggests the Hawthorne effect resulted from operant reinforcement contingencies

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Block design allowed for control of the Hawthorne effect in a randomized controlled trial of test ordering

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

The ‘Wise List’- A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Association of Treatment With Losartan vs Candesartan and Mortality Among Patients With Heart Failure

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12130

21 January 2018

Identifiers

10.1111/IJCP.12130

1 reference

Europe PubMed Central

28 August 2017

1 reference

Europe PubMed Central

28 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38096468&oldid=1741111424"